Pretax income is the income that a company earns before paying income taxes. SILO Pharma's pretax income for the
three
months ended in Dec. 2024 was $-1.73 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-4.39 Mil.
SILO Pharma's pretax margin was -9,616.67%.
During the past 13 years, SILO Pharma's highest Pretax Margin was 5890.14%. The lowest was -6102.78%. And the median was -2470.73%.
SILO Pharma Pre-Tax Income Historical Data
The historical data trend for SILO Pharma's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SILO Pharma's Pre-Tax Income
For the Biotechnology subindustry, SILO Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where SILO Pharma's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (NAS:SILO) Pre-Tax Income Explanation
SILO Pharma's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 13 years, SILO Pharma's highest Pretax Margin was 5890.14%. The lowest was -6102.78%. And the median was -2470.73%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of SILO Pharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SILO has been successfully added to your 